Table 1 Baseline demographics and disease characteristics for patients enrolled in studies of IV golimumab in RA, PsA, and AS*

Patients, N

197

395

239

241

103

105

 Mean age, years (range)

51.4 (19, 78)

51.9 (18, 83)

46.7 (18, 79)

45.7 (19, 69)

39.2 (20, 67)

38.4 (19, 64)

 Male, n (%)

40 (20.3)

69 (17.5)

121 (50.6)

128 (53.1)

77 (74.8)

86 (81.9)

 BMI, kg/m²

27.0 (5.7)

26.8 (5.5)

28.9 (6.2)

28.9 (6.4)

26.8 (6.4)

27.2 (5.9)

 Disease duration, years

7.0 (7.2)

6.9 (7.0)

5.3 (5.9)

6.2 (6.0)

5.5 (5.9)

5.6 (6.6)

 Swollen Joint count (0–66)

14.8 (8.5)

15.0 (8.2)

14.1 (8.2)

14.0 (8.4)

–

–

 Tender joint count (0–68)

25.9 (14.1)

26.4 (13.9)

26.1 (14.4)

25.1 (13.8)

–

–

 CRP, mg/dL

2.2 (1.9)

2.8 (2.9)

2.0 (2.0)

1.9 (2.5)

1.9 (1.7)

2.0 (1.8)

 BASDAI, N

–

–

53**

56**

103

105

  Score

–

–

6.4 (1.9)

6.5 (1.8)

7.1 (1.2)

7.0 (1.2)

 Methotrexate, n (%)

197 (100)

395 (100)

173 (72.4)

163 (67.6)

21 (20.4)

16 (15.2)

  Dose, mg/week

16.6 (2.8)

16.8 (2.9)

14.9 (4.8)

14.8 (4.7)

13.7 (5.0)

16.7 (4.9)

 Oral corticosteroids, n (%)

134 (68.0)

251 (63.5)

67 (28.0)

66 (27.4)

23 (22.3)

32 (30.5)

  Dose***, mg/day

7.0 (2.5)

7.0 (2.5)

7.6 (2.5)

7.4 (2.6)

6.1 (2.5)

7.8 (2.7)

 NSAIDs, n (%)

156 (79.2)

323 (81.8)

167 (69.9)

173 (71.8)

90 (87.4)

94 (89.5)